Tudor Investment Corp
DSGN icon

Tudor Investment Corp’s Design Therapeutics DSGN Stock Holding History

Tudor Investment Corp’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,738
Closed -$101K – 3123
2024
Q3 		$101K Sell
18,738
-1,127
-6% -$5.3K ﹤0.01% 2596
2024
Q2 		$66.5K Sell
19,865
-5,462
-22% -$21.3K ﹤0.01% 2220
2024
Q1 		$102K Buy
+25,327
New +$67.6K ﹤0.01% 2093
2023
Q4 		– Sell
-16,299
Closed -$38.5K – 2472
2023
Q3 		$38.5K Sell
16,299
-4,262
-21% -$19.9K ﹤0.01% 2192
2023
Q2 		$130K Sell
20,561
-7,078
-26% -$43.3K ﹤0.01% 2280
2023
Q1 		$159K Buy
27,639
+9,955
+56% +$74.5K ﹤0.01% 2209
2022
Q4 		$181K Sell
17,684
-10,182
-37% -$138K ﹤0.01% 2152
2022
Q3 		$466K Buy
27,866
+14,966
+116% +$298K 0.01% 1453
2022
Q2 		$181K Buy
+12,900
New +$174K ﹤0.01% 1850

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tudor Investment Corp's DSGN Position: Q4 2024 in Review

Tudor Investment Corp sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 18,738 shares — an estimated $101K sold.

Tudor Investment Corp first reported a position in DSGN in Q2 2022 and held it in 9 quarters. The position peaked at $466K in Q3 2022. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Tudor Investment Corp reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Tudor Investment Corp sold 18,738 Design Therapeutics shares in Q4 2024, an estimated $101K.
  • Tudor Investment Corp first reported a position in Design Therapeutics in Q2 2022 and held it in 9 quarters.
  • Tudor Investment Corp's Design Therapeutics position peaked at $466K in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.